Search for: "State of IN v. Amgen, Inc., et al"
Results 21 - 40
of 75
Sort by Relevance
|
Sort by Date
15 Jun 2017, 2:09 pm
In SANDOZ INC. v. [read post]
15 Jun 2017, 2:09 pm
In SANDOZ INC. v. [read post]
12 Apr 2017, 5:00 am
Doe et al., No. 16-222-cv, 2016 BL 292694 (2d Cir. [read post]
8 Feb 2017, 3:09 am
(Appeal from MD State Court) Anticipation/Obviousness: Google Inc., et al. v. [read post]
18 Jan 2017, 6:40 am
– Amgen, Inc. v. [read post]
16 Jan 2017, 5:44 pm
(Appeal from MD State Court) Anticipation/Obviousness: Google Inc., et al. v. [read post]
12 Jan 2017, 7:01 am
Amgen Inc., et al., 15-1039 and Amgen Inc. v. [read post]
14 Nov 2016, 9:16 am
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Licensing: DataTreasury Corp. v. [read post]
13 Oct 2016, 6:50 am
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Eligibility: Trading Technologies International, Inc. v. [read post]
28 Sep 2016, 8:39 am
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Mylan Pharmaceuticals, et al. v. [read post]
28 Jun 2016, 6:41 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
3 Jun 2016, 6:40 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
18 May 2016, 8:19 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
3 May 2016, 1:42 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
18 Apr 2016, 9:58 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
1 Apr 2016, 8:22 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
17 Mar 2016, 2:45 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
4 Mar 2016, 12:25 pm
Daiichi Sankyo, Inc., et al. v. [read post]
8 Nov 2015, 9:20 pm
Amgen Inc. et al. v. [read post]
30 Sep 2015, 4:30 am
Amgen, Inc., et al., Case No. 2:12-cv-476 (M.D. [read post]